← back to search

Catherine Egan

Government of the United Kingdom ·
Area of research
Ophthalmology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Retinal Diseases and Treatments, Retinal Imaging and Analysis, Retinal and Optic Conditions, and Glaucoma and retinal disorders.
h-index
54
citations
10,915
works
330
NIH funding
primary concept
email

Recent publications

Multi-omic spatial effects on high-resolution AI-derived retinal thickness
Nature Communications 2025cited by 26position: middledoi
Machine learning derived retinal pigment score from ophthalmic imaging shows ethnicity is not biology
Nature Communications 2025cited by 12position: middledoi
Artificial intelligence-supported diabetic retinopathy screening in Tanzania: rationale and design of a randomised controlled trial
BMJ Open 2024cited by 14position: middledoi
Divergent amino acid and sphingolipid metabolism in patients with inherited neuro-retinal disease
Molecular Metabolism 2023cited by 16position: middledoi
UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
Eye 2022cited by 35position: middledoi
Outreach screening to address demographic and economic barriers to diabetic retinopathy care in rural China
PLoS ONE 2022cited by 4position: middledoi
Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy
New England Journal of Medicine 2019cited by 250position: middledoi
Clinically applicable deep learning for diagnosis and referral in retinal disease
Nature Medicine 2018cited by 2,572position: middledoi
Effects of Topically Administered Neuroprotective Drugs in Early Stages of Diabetic Retinopathy: Results of the EUROCONDOR Clinical Trial
Diabetes 2018cited by 92position: middledoi
Safety and Feasibility of a Novel Sparse Optical Coherence Tomography Device for Patient-Delivered Retina Home Monitoring
Translational Vision Science & Technology 2018cited by 56position: middledoi
Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial
The Lancet Diabetes & Endocrinology 2018cited by 33position: middledoi
Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project
Diabetes 2017cited by 154position: middledoi
Genome-wide analyses identify common variants associated with macular telangiectasia type 2
Nature Genetics 2017cited by 136position: middledoi
Black patients sustain vision loss while White and South Asian patients gain vision following delamination or segmentation surgery for tractional complications associated with proliferative diabetic retinopathy
Eye 2017cited by 19position: middledoi
UK AMD EMR USERS GROUP REPORT V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6/12
British Journal of Ophthalmology 2015cited by 59position: middledoi
Retinal Layer Location of Increased Retinal Thickness in Eyes with Subclinical and Clinical Macular Edema in Diabetes Type 2
Ophthalmic Research 2015cited by 59position: middledoi
Characterization of Retinal Disease Progression in a 1-Year Longitudinal Study of Eyes With Mild Nonproliferative Retinopathy in Diabetes Type 2
Investigative Ophthalmology & Visual Science 2015cited by 24position: middledoi
One-Year Progression of Diabetic Subclinical Macular Edema in Eyes with Mild Nonproliferative Diabetic Retinopathy: Location of the Increase in Retinal Thickness
Ophthalmic Research 2015cited by 21position: middledoi
“En face” OCT Imaging of the IS/OS Junction Line in Type 2 Idiopathic Macular Telangiectasia
Investigative Ophthalmology & Visual Science 2012cited by 103position: middledoi
The IS/OS Junction Layer in the Natural History of Type 2 Idiopathic Macular Telangiectasia
Investigative Ophthalmology & Visual Science 2012cited by 78position: middledoi
The effect of low vision rehabilitation in diabetic eye disease: a randomised controlled trial protocol
Ophthalmic and Physiological Optics 2012cited by 7position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Francesco Bandello · Frimley Health NHS Foundation Trust4 papers (2015–2017)José Cunha‐Vaz · University of Padua4 papers (2015–2017) · 4 papers (2015–2017)Adnan Tufail · Moorfields Eye Hospital NHS Foundation Trust4 papers (2015–2025) · 4 papers (2015–2017) · 3 papers (2015–2015)Stela Vujosevic · University of Padua3 papers (2015–2015) · 3 papers (2015–2015)Melanie Bahlo · The University of Western Australia3 papers (2017–2025)Sobha Sivaprasad · UK Biobank3 papers (2015–2015) · 3 papers (2015–2015)Henrik Lund‐Andersen · Steno Diabetes Centers3 papers (2015–2015) · 3 papers (2015–2015) · 3 papers (2015–2015) · 3 papers (2015–2015)Giuseppe Querques · Novartis (Switzerland)3 papers (2015–2015)Monica Varano · Novartis (Switzerland)3 papers (2015–2015) · 3 papers (2017–2025)Frank G. Holz · Tsinghua University3 papers (2015–2015) · 3 papers (2015–2015)